TScan Therapeutics (TCRX) Common Equity (2020 - 2026)
TScan Therapeutics (TCRX) posted quarterly Common Equity of $96.9 million for Q1 2026, down 53.89% year-over-year from $210.2 million in Q1 2025, and down 21.28% quarter-over-quarter from $123.1 million in Q4 2025.
TScan Therapeutics (TCRX) Common Equity (2020 - 2026) Analysis & Trends
TScan Therapeutics (TCRX) has reported Common Equity for 7 consecutive years, with $96.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Common Equity fell 53.89% year-over-year to $96.9 million; the TTM figure through Mar 2026 stood at $96.9 million (down 53.89% YoY), while the FY2025 annual figure was $123.1 million, down 48.91% from the prior year.
- Common Equity fell to $96.9 million in Q1 2026 per TCRX's latest filing, from $123.1 million in the prior quarter.
- Across five years, Common Equity topped out at $255.2 million in Q2 2024 and bottomed at $78.0 million in Q1 2023.
- Historically, Common Equity has averaged $157.7 million across 5 years, with a median of $145.7 million in 2022.
- Annual changes were most pronounced in 2022 — Common Equity soared 391.84% — and 2026, when it tumbled 53.89%.
- TScan Therapeutics' Common Equity stood at $99.4 million in 2022, then surged by 51.73% to $150.9 million in 2023, then jumped by 59.72% to $241.0 million in 2024, then slumped by 48.91% to $123.1 million in 2025, then declined by 21.28% to $96.9 million in 2026.
- Business Quant data shows TCRX's Common Equity at $96.9 million in Q1 2026, $123.1 million in Q4 2025, and $144.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.79 Bn |
| 10 | TScan Therapeutics | 100.62 Mn | 100.62 Mn | - | 69.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 69.02 Mn |
| Mar 31, 2026 | 96.92 Mn |
| Dec 31, 2025 | 123.12 Mn |
| Sep 30, 2025 | 144.02 Mn |
| Jun 30, 2025 | 176.71 Mn |
| Mar 31, 2025 | 210.20 Mn |
| Dec 31, 2024 | 240.97 Mn |
| Sep 30, 2024 | 229.09 Mn |
| Jun 30, 2024 | 255.22 Mn |
| Mar 31, 2024 | 122.97 Mn |
| Dec 31, 2023 | 150.87 Mn |
| Sep 30, 2023 | 168.96 Mn |
| Jun 30, 2023 | 190.61 Mn |
| Mar 31, 2023 | 78.02 Mn |
| Dec 31, 2022 | 99.43 Mn |
| Sep 30, 2022 | 116.66 Mn |
| Jun 30, 2022 | 131.65 Mn |
| Mar 31, 2022 | 145.69 Mn |
| Dec 31, 2021 | 160.78 Mn |
| Sep 30, 2021 | 174.07 Mn |